BeyondSpring, Inc. - Ordinary Shares (BYSI): Price and Financial Metrics


BeyondSpring, Inc. - Ordinary Shares (BYSI)

Today's Latest Price: $11.19 USD

0.30 (2.75%)

Updated Nov 27 1:00pm

Add BYSI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

BYSI Stock Price Chart Interactive Chart >

Price chart for BYSI

BYSI Price/Volume Stats

Current price $11.19 52-week high $21.50
Prev. close $10.89 52-week low $9.38
Day low $10.70 Volume 688,389
Day high $11.35 Avg. volume 141,476
50-day MA $14.13 Dividend yield N/A
200-day MA $14.16 Market Cap 341.47M

BeyondSpring, Inc. - Ordinary Shares (BYSI) Company Bio


BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies. The co is advancing its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia.


BYSI Latest News Stream


Event/Time News Detail
Loading, please wait...

BYSI Latest Social Stream


Loading social stream, please wait...

View Full BYSI Social Stream

Latest BYSI News From Around the Web

Below are the latest news stories about BeyondSpring Inc that investors may wish to consider to help them evaluate BYSI as an investment opportunity.

BeyondSpring's manuscript on Plinabulin published in JAMA Oncology

JAMA Oncology, the American Medical Association’s peer-reviewedjournal published  BeyondSpring's ([[BYSI]] -0.3%) manuscript, titled 'Efficacy of Plinabulin vs. Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer.'The manuscript analyzed company’s Phase 2 portion of its PROTECTIVE-1 randomized clinical trial, which consisted of four treatment arms and was conducted in 19 treatment centers...

Seeking Alpha | September 29, 2020

BeyondSpring EPS beats by $0.11

BeyondSpring (BYSI): Q2 GAAP EPS of -$0.46 beats by $0.11.Cash and cash equivalents of $38.08M.Press Release...

Seeking Alpha | September 3, 2020

New Stem Cell-Based Application for BeyondSpring’s Plinabulin Presented at ISSCR Annual Meeting

BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company presented clinical data on BeyondSpring’s first-in-class, late-stage asset, Plinabulin, showing potent CD34+ progenitor cell mobilization from bone marrow, which has broad applications for stem cell-based therapies, gene therapy and regenerative medicine. Dr. Ramon Mohanlal, BeyondSpring’s Chief Medical Officer and Executive Vice President, Research and Development, presented this new data as a poster at this year’s ISSCR Annual Meeting.

Yahoo | June 30, 2020

BeyondSpring (BYSI) Catches Eye: Stock Jumps 10.9%

BeyondSpring (BYSI) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

Yahoo | June 24, 2020

New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring’s Plinabulin

BeyondSpring (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology (I/O) therapies, today announced new preclinical research findings that indicate BeyondSpring’s lead asset, Plinabulin, enhances immuno-radiotherapy for cancer patients. Based on these preclinical findings, including a 100% complete response of the triple I/O combination of Plinabulin, anti-PD-1, and radiation in a PD-1 antibody non-responsive model, the compound is being advanced toward a Phase 1 clinical trial in patients who failed or progressed on PD-1 / PD-L1 antibody treatments. Principal investigator Steven H. Lin, M.D., Ph.D., associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, presented t...

Yahoo | June 23, 2020

Read More 'BYSI' Stories Here

BYSI Price Returns

1-mo -23.30%
3-mo -8.20%
6-mo -34.18%
1-year -13.99%
3-year -66.96%
5-year N/A
YTD -27.81%
2019 -17.33%
2018 -35.52%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8567 seconds.